think empir strike back year assum coverag ow rate
assum coverag ow rate pt
risk monitor slower end market share eros certain area
believ stock reflect compani upcom product cycl view quit
strong believ consider margin expans front compani
go along best med tech strong balanc sheet
boot dividend payment sharehold friendli activ collect
believ compani beat expect top- bottom line come
quarter along discount multipl versu peer group set share
outperform opinion larg cap med tech name consequ
encourag investor start build posit name
top line believ conserv given former
miss compani benefit meaning product cycl fiscal
tavr lvad micra cvg multipl mitg launch guardian connect
diabet enabl mid-singl digit adjust revenu growth
addit believ signific opportun improv margin
multi-year period strategi lower cog manufactur improv
facil consolid leverag ebit commerci function
optim yield strong ep growth go along best
gener capit return sharehold med tech
con bear stori continu focu slower growth end market
spine anniversari certain product cycl increas competit
major categori execut somewhat mix past
year caus investor view name show stori lastli bit less
excit mdt value-bas care model see increment benefit
compani
stock thought current trade consensu cy ep estim
discount larg cap medic devic stock exclud
view discount unwarr given compani solid top-lin growth
outlook mid-singl digit improv margin drive solid ep growth high-singl
low-doubl digit think compani trade premium larg
cap group line strong margin stori name
consequ initi coverag overweight rate price
target base calendar ep estim
slowdown key market competit pressur regulatori delay
largest medic technolog compani global diversifi product offer
cardiolog surgeri spine neurolog diabet
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
assum coverag overweight rate pt
despit temper expect sever key market compani set benefit
meaning product cycl corevalv lvad micra multipl mitg launch
guardian connect etc believ collect drive solid revenu growth mid-singl
digit believ signific opportun improv margin gross ebit
multi-year period compani implement strategi leverag
yield strong ep growth go along best gener return
sharehold med tech
share lag larg cap med tech year stock trade
calendar ep estim peer group exclud question
whether stock room bridg delta come quarter view discount
unwarr given compani solid top-lin growth outlook mid-singl digit improv
profit profil drive solid ep growth high-singl low-doubl digit think
compani trade premium overal larg cap group line strong
margin stori compani view compani deliv
upsid number give investor renew convict manag abil execut
suspect skeptic current price stock drive multipl
stock higher consequ initi coverag overweight rate
price target base cy ep estim
factset price close
benefit meaning product cycl fiscal allow compani
deliv mid-singl digit revenu growth believ conserv top
line outlook given previou miss benefit meaning product cycl fiscal
corevalv lvad micra multipl mitg launch guardian connect etc thu allow
compani meet exceed guidanc view growth area core
spine slow growth area tavr diabet along
improv growth mitg covidien make mid-singl digit overal top line growth
sustain addit compani still signific opportun grow busi
intern specif emerg market repres revenu today
go along steadi domest franchis
page
dickinson scientif lifesci biomet hold cap ev/sal exhibit
expect growth driver product launch
cardiac vascular cvg number key product perhap
import driver corevalv famili tavr minim invas method treat sever
aortic stenosi narrow aortic valv seen inflect clinician interest due
recent data efficacy/cost front rel surgic method savr estim ww
tavr market current grow line edward lifesci
estim ew cover would make categori one fastest grow market
med tech primari player ew sapien corevalv product
lesser extent lotu though current market acur neo former
mdt third-gener system corevalv evolut receiv fda approv march
expand label includ intermedi risk patient juli total sever
symptomat patient lastli note price remain concern investor
market eventu addit player larger presenc potenti abbott
w/ portico cover said data present check tct show price
still enabl materi cost save via shorten recoveri time hospit relat cost vs savr
think price get impact much especi near term
pacer icd face declin growth matur market
meaning share compani recogn dynam focus innov product like
micra miniatur singl chamber pacemak bradycardia slow beat heart place
directli right ventricl wherea convent pacemak leads/wir go
heart pacemak serv us patient popul littl bit
europ next gener abil sens atrial contract pace
ventricl would bring address patient popul compani receiv
solid adopt thu far micra help compani captur share gain
page
growth evolut corevalv evolut tmvrlvadsresolut onyxlvad thoracotomylow risk tavr indic diagnosticsmicra reimbursementtyrx wrap clinic datamvadaflvad venas closur systemmicra expansionmicraavalu surgic valveseeq extend holterren denervationtyrxrev linq stroke ev icdsazur wireless pacemak mitgadvanc product expect product expect energysignia staplersurg roboticsgi solutionsligasur vessel sealingport hemodialysi systemgynecologyrenalrtgneurovascularintellisdb epilepsi us cranial mount dbsneurosurgerymazor partnershipmazormedina intrasaccular transform solutionsvoyag neuromodprestig lpdirect stim db leadnerv integr monitor tibial nerv stimpow bone biopsymaverick divertermida drillinfus indic expansiondiabetespumpsminim usguardian connectnext sensorsensorsmio ousadvanc cl algosnew insulin deliveri system
tradit space declin devic come price standard pacemak
reimburs place march captur revenu share
also particip heart failur space innov therapi lvad
came acquisit heartwar space categori grow
high singl digit ww obtain destin therapi indic fda
compani product see strong uptak us thu far remind dt market
much larger bridge-to-transpl categori go forward compani plan us
thoracotomi indic japan hvad launch expect product watch
within cvg includ resolut onyx next gen de artic front advanc cryoablat
balloon af tyrx absorb antibacteri envelop reveal linq icm diagnost
minim invas therapi group mitg franchis decent grower
recent quarter expect much improv profil come year
shift open mi procedur continu support new product innov
come next three year specif detail limit point mitg split
surgic innov respiratori gastrointestin renal surgic
innov two subcategori advanc surgic advanc stapl advanc
energi hernia gynecolog intervent lung grow high singl digit gener
surgic sutur instrument grow mid-singl digit advanc surgic
eventu includ compani robot system discuss detail later
report advanc ablat gi solut renal primari driver given covidien
strong sale channel expect pull-through dynam increasingli emerg new product
cycl mitg collect repres sever billion-dollar categori import
intervent lung advanc ablat technolog gynecolog hernia gi solut
restor therapi group rtg slower market worst
headwind may rearview think new product momentum act stabil
busi near-term first compani experienc declin core spine given
pressur market increasingli focus enabl technolog pair
categori invest mazor robot infus biolog product
rel new indic brain therapi divis neurovascular neurosurgeri
neuromodul move part continu retain global
leadership posit number categori back broad portfolio therapi
first neurovascular segment solid momentum stroke doubl digit almost
geographi stent lead way second neurosurgeri stealthstat ldd grower
last neuromodul continu inund competit headwind pain side
scs/pump franchis bit less challeng recent given lift consent
decre though put dent mdt innov pipelin commerci capabl
past coupl year said think competit pressur like linger
last certainli least diabet compani sell number product insulin
pump continu glucos monitor cgm system manag softwar far
market leader pump market share cgm market share
trail pump side key growth driver compani hybrid close loop
system minim given exit roch anima cover last year
pump market three primari player us anima
patient still choos provid believ win major patient sinc
facilit transit custom devic done number kol call
check align viewpoint recent jnj diabet busi declin
page
rapid pace expect could impli former anima patient switch sooner
expect plu uptak pump product
cgm believ growth market acceler still signific
penetr opportun particularli introduct abbott low cost libr dxcm
medicar recent approv continu data read highlight benefit
cgm lower level type type patient mdt guardian connect cgm
system recent receiv fda approv diabet age product last day
receiv non-adjunct claim replac finger stick like libr
receiv medicar coverag
said get claim current file sensor recent receiv new arm
indic get mard measur accuraci product
threshold need non-adjunct use thu eventu expect get non-
adjunct claim unsur time key advantag compani
power payer relationship potenti bundl servic view guardian connect
differenti libr expect cgm sell end
day believ pump compani first use sensor support
system term futur product launch continu work toward true closed-loop
system alreadi start talk look updat
pipelin strategi upcom ada confer june
lastli enhanc go-to-market strategi specif emerg market decid
go direct certain place new product cycl compani meaning
opportun grow emerg market current repres around revenu
base grow doubl digit geographi focus go direct
abl get growth way possibl vs use distributor go direct
expens compani claim creat cost save along way channel
optim strategi term potenti upcom chines tariff exact effect still
unclear point worth note mani product produc sold china
em revenu base region
earn power strong improv revenu profil flow nice
view next sever year plan expand oper margin
basi point constant currenc driven continu covidien synergi lever
near term drive gm op margin leverag leverag annual save
compani aim deliv fy start base last fiscal year
increment per year period back end load closer lower
end rang earlier year upper end later year overal core piec
thesi name believ initi improv revenu growth flow
nice expand margin help drive ep growth next sever year
among best larg cap med tech get investor interest name
manag hit previous estim covidien cost synergi year year
mostli sg model specif covidien upsid believ
number synergi catalyst long-term opportun drive leverag
mani begin materi year specif anticip optim sale
forc system manufactur organiz cost begin benefit margin company-
wide on-going leverag facilit go forward compani cog reduct
plan on-going includ improv manufactur sourc initi plu reduc
number product site would drive total cog spend
per year next year plan may seem aggress view
alreadi start make headway initi place deliv target
page
move incom statement optimist opportun improv
ebit margin addit cost plan discuss manag done nice job
year keep eye price pressur number market divest slower-growth
asset patient deep vein thrombosi nutrit insuffici busi
covidien cardin part enterpris excel initi
improv share servic back offic effici across entir global platform better
serv custom save sg cost
product pipelin year robust view help achiev
premium multipl abund product note schedul year
next compani also number develop program long term
import purpos report pull program believ could
biggest impact name robot mitral valv product multipl
year away launch believ serv call option help achiev
robot compani work first gener surgic robot system eventu
compet isrg da vinci platform find robot opportun key focu investor
expect come quarter year number minim invas robot
technolog set increas in-hous robot platform develop
nearli year compani employe three offic work
platform time perspect anticip first-in-man procedur sometim late
delay recent earn call exact time unknown point
anticip launch start india launch eu us pend
regulatori approv revenu standpoint compani previous talk revenu
meaning mitg note depend regulatori approv
robot eventu launch manag say capabl everi
procedur current robot offer perform understand plan robot
provid procedur offer current devic market includ bariatr thorac
colorect gener surgeri urolog gynecolog still stress one major
benefit platform cost expect demonstr amount favor
econom outcom data compet effect
believ launch put much dent isrg posit near-monopolist
leader massiv instal base superior mean capit resourc
perspect view rel potenti competitor certainli make robot worth
keep eye although need introduc signific number robot instrument
take long time accomplish mani detail unknown point price exact target
procedur etc expect compani provid deeper insight program throughout
calendar perhap upcom analyst day june
second program transcathet mitral valv replac tmvr market
investor sure key technolog might next multibillion dollar market
opportun med tech mitral regurgit common heart valv diseas
procedur per year though given high-risk natur exist surgic procedur
signific treatment gap remain similar uptak tavr longer time frame tmvr
potenti upend current treatment option patient mitral regurgit could
larger market opportun tavr tmvr remain bullish intrepid
mitral replac system altern repair clinic standpoint
page
first tmvr pivot trial call apollo began enrol octob
enrol one-year result expect
term could drive futur success market look discuss
clinician industri confer attend larg tct meet physician cite
transsept deliveri access valv femor arteri similar tavr
access mitral valv septal punctur one key success
commerci tmvr come year approach carri less risk patient
though mdt intrepid product trans-ap approach compani expect fulli trans-sept
fulli retriev next-gen platform roll current enrol trial
avail calendar year
heard multipl repair replac technolog like requir
success market intrepid current one product develop compar
four mitral program edward cardiaq cardioband harpoon pascal two
caisson highlif one abbott tendyn result believ want
compet effect futur like go acquir compani mitral space
clearli much work need categori continu monitor
progress come year
free cash flow capit return sharehold among best med tech
increasingli best free cash flow gener med tech defin
oper cash flow less capit expenditur well solid track record pay capit
sharehold plan return least free cash flow per year combin
dividend share repurchas covidien deal increas mdt avail us
covidien cash access gener
given expect revenu growth expans oper margin step-up effici
expect grow roughli line earn multi-year period model
model compani net debt/ebtida declin
maintain pay-out ratio
factset price close
page
free return sharehold
could wrong bear stori continu focu slower growth end
market spine anniversari certain product cycl increas
competit major product categori execut somewhat mix past
year caus investor view name show stori mani believ longer-
term guidanc look somewhat optimist top line oper margin certainli
execut risk monitor potenti miss lower l-t guidanc would weigh
stock
second less excit mdt model value-bas care howev compani
like number wall street analyst believ develop specif measur pre-
defin patient outcom paramount gain quantifi object result serv
basi bundl strategi think given still earli inning
shift value-bas care mdt low-risk entri merit given evolv dynam
compani much flexibl iter evolv landscap continu chang
interest theori think mdt value-bas care model hospit pay base actual
achiev outcom take time efficaci need proof model
work long dynam take benefit compani revenu cost
sign nearli contract requir pay hospit tyrx antibacteri
sleev prevent infect point revenu us tie
risk-shar account overal term area might interest episod bundl
futur manag highlight cabg pci spine potenti chronic diseas state
diabetes/end-stag renal diseas could wrong increment opportun
would receiv arrang number larg contract may abl
garner come quarter year
lastli certainli addit risk monitor thesi price pressur key
market spine lower expect revenu growth and/or margin expans greater
expect share eros larg categori structur heart surgeri diabet regulatori delay
key product litig reimburs pressur
page
oper growth margin return busi segment
overview
largest stand-alone medic technolog compani global product offer
number vertic includ cardiolog vascular surgeri spine neurolog diabet
januari bought covidien enterpris valu repres
largest transact med tech industri histori transact compani chang
headquart dublin ireland tax invers strategi oper headquart
minneapoli current employ nearli peopl global post
revenu fy revenu us intern current compani
oper four main segment cardiac vascular group minim invas therapi group
restor therapi group diabet group
cardiac vascular group medtron cardiac vascular group compani largest
busi line sale segment cardiac rhythm heart failur chrf coronari
 structur heart csh aortic peripher vascular apv cvg account
revenu fy includ estim
cardiac rhythm heart failur divis total revenu largest piec
cvg includ devic therapi treat abnorm heart rhythm cardiac diagnost
monitor solut crhf group consist arrhythmia manag grow mid-
singl digit heart failur grow high singl digit arrhythmia manag
includ pacemak icd declin lsd diagnost low dd af high teen bread
butter includ pacemak implant cardiovert defibril also known
icd excel therapi solid data penetr categori high
mean market grow quickli
within cvg coronari structur heart busi key tavr
grow mid coronari ldd includ key resolut onyx drug elut
stent de product lastli aortic peripher vascular divis focus treat aortic
diseas abdomin aortic aneurysm dissect transect vascular diseas
peripher vascular diseas critic limb ischemia peripher endo side grow
msd pta balloon growth asset compani market leader
dcb grow fast aortic product grow lsd collect major
come intern market
minim invas therapi group segment brought covidien
acquisit consist two divis surgic innov respiratori
gastrointestin renal collect repres sale
page
modelpip modelarrhythmia lsdheart failur msdservic solut low rhythm heart valv therapi mid therapi msdcoronari structur lsdperipher endoven msdaortic peripher exhibit
recategor certain busi line within mitg compani divest
patient compress nutrit busi within previous report patient monitor
recoveri segment advanc surgic encompass prior earli technolog
segment longer report includ intervent lung advanc ablat
respiratori gastrointestin renal within surgic innov busi compani
sell varieti product treat diseas typic address surgeon exclus
advanc surgic gener surgic hernia within categori advanc
surgic grow high singl digit gener surgic wound closur mostli grow mid-
singl digit advanc surgic eventu includ compani robot system
discuss detail later report
second within respiratori gastrointestin renal divis compani broad
portfolio treatment renal diseas product includ dialysi cathet renal
therapi access fistula cannula cannul dialysi treatment comprehens
portfolio equip consum perform dialysi treatment acut
restor therapi group group repres overal revenu
includ spine brain therapi specialti therapi pain therapi
certainli issu within overal spine market compani biolog
product infus quit well within brain therapi franchis compani sell
page
product deep brain stimul db treat varieti condit includ parkinson
essenti tremor well neurosurgeri product platform technolog implant
anticip part busi grow quickli mani year come specialti
therapi divis includ pelvic health gastric ent advanc energi lastli
compani pain therapi divis includ neurostimul system implant
system less excit due competit headwind temper growth rate
diabet group diabet group repres ww revenu consist intens
insulin manag type non-intens diabet therapi pre-diabet type
diabet servic solut collect includ product insulin pump therapi
continu glucos monitor cgm system therapi manag softwar
far market leader pump market share cgm market
share trail key growth driver compani hybrid close loop system
minim discuss previous compani also sell guardian connect cgm
continu expect revenu growth constant currenc
bottom line reiter guidanc call expect adjust ep growth
rang cc current exchang rate expect currenc impact
full year cent neg impact fourth fiscal quarter includ fiscal
estim model y/i cc revenu growth report progress
incom statement model decent bump gross margin around basi point
year also model sg leverag remaind year
larg driven improv mix cost initi push oper margin estim
adjust basi combin factor result adjust ep
y/i
look model constant currenc revenu growth sale
similar last year believ main revenu driver diabet tavr
addit product launch mitg increment expect msd organ
revenu growth cvg mitg rtg grow msd diabet grow dd current
rate fx expect p/ tailwind compani expect provid full
guidanc call may investor day plan new york june
gross margin side model anoth bp expans
model sg leverag roughli bp outlook percentag revenu
lower compar taken expens estim roughli
last year tax rate unlik benefit tax reform model
ep y/i
page
healthi balanc sheet larg cap medic technolog compani though
compani pay debt associ covidien transact consequ unlik
mani similar compani space flush cash per se fiscal
sit net debt posit howev come year compani
increasingli abl access free cash flow order pay debt execut
acquisit return capit sharehold compani signific amount goodwil
intang balanc sheet tune associ covidien
mdt dso reason day much like rest larg cap med tech inventori
day hand sizeabl liabil side balanc sheet current
carri debt ebitda leverag ratio
far cash flow statement goe mdt ocf declin rel recent year
believ figur rise meaning start compani capit expens
requir in-lin larg med tech compani sale
includ estim model mdt
page
million except per share data
good sold
percent sale
good sold
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
